Evidence map›Paper›PMID 31036442›Full record

ArticleEuropean urology2019

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.

Adam Sharp, Jon C Welti, Maryou B K Lambros, David Dolling, Daniel Nava Rodrigues, Lorna Pope, Caterina Aversa, Ines Figueiredo, Jennifer Fraser, Zai Ahmad and 25 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in European urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 4 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 4 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Advances in Prostate Cancer Biomarkers and Probes.Cyborg and bionic systems (Washington, D.C.) · 2024
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 6 institutions in 4 countries.

Adam SharpThe Institute for Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
Jon C WeltiThe Institute for Cancer Research, London, UK.
Maryou B K LambrosThe Institute for Cancer Research, London, UK.
David DollingThe Institute for Cancer Research, London, UK.
Daniel Nava RodriguesThe Institute for Cancer Research, London, UK.
Lorna PopeThe Institute for Cancer Research, London, UK.
Caterina AversaThe Royal Marsden NHS Foundation Trust, London, UK.
Ines FigueiredoThe Institute for Cancer Research, London, UK.
Jennifer FraserThe Institute for Cancer Research, London, UK.
Zai AhmadThe Institute for Cancer Research, London, UK.
Changxue LuJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Pasquale RescignoThe Institute for Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK; University of Naples Federico II, Naples, Italy.
Michael KolinskyUniversity of Alberta, Edmonton, Alberta, Canada.
Claudia BertanThe Institute for Cancer Research, London, UK.
George SeedThe Institute for Cancer Research, London, UK.
Ruth RiisnaesThe Institute for Cancer Research, London, UK.
Susana MirandaThe Institute for Cancer Research, London, UK.
Mateus CrespoThe Institute for Cancer Research, London, UK.
Rita PereiraThe Institute for Cancer Research, London, UK.
Ana FerreiraThe Institute for Cancer Research, London, UK.
Gemma FowlerThe Institute for Cancer Research, London, UK.
Berni EbbsThe Institute for Cancer Research, London, UK.
Penny FlohrThe Institute for Cancer Research, London, UK.
Antje NeebThe Institute for Cancer Research, London, UK.
Diletta BianchiniThe Royal Marsden NHS Foundation Trust, London, UK.
Antonella PetremoloThe Royal Marsden NHS Foundation Trust, London, UK.
Semini SumanasuriyaThe Institute for Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
Alec PaschalisThe Institute for Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
Joaquin MateoVall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Nina TunariuThe Royal Marsden NHS Foundation Trust, London, UK.
Wei YuanThe Institute for Cancer Research, London, UK.
Suzanne CarreiraThe Institute for Cancer Research, London, UK.
Stephen R PlymateUniversity of Washington and VAPSHCS GRECC, Seattle, WA, USA.
Jun LuoJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Johann S de BonoThe Institute for Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: Johann.de-Bono@icr.ac.uk.
Royal Marsden NHS Foundation Trust · GBJohns Hopkins Medicine · USJohns Hopkins University · USUniversity of Alberta · CAUniversity of Washington · USVall d'Hebron Institute of Oncology

Funding

Steroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PETER S NELSON · 2013 to 2026
$25.0M
The aberrant androgen receptor underlies abiraterone/enzalutamide resistanceR01CA185297 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANTONARAKIS, EMMANUEL S., LUO, JUN · 2015 to 2018
$1.5M
Mechanisms for the Transition to Castrate Resistant Prostate CancerI01BX000585 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI PLYMATE, STEPHEN R. · 2009 to 2013
–
Targeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate CancerI01BX003324 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI PLYMATE, STEPHEN R. · 2016 to 2024
–
BLRD VA I01 BX000585BLRD VA I01 BX003324Medical Research Council MR/M018318/1NCI NIH HHS P01 CA163227NCI NIH HHS R01 CA185297
6 · The paper itself

Abstract

backgroundDetection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant prostate cancer (mCRPC). However, studies rarely report comparisons with CTC counts and biopsy AR-V7 protein expression.

objectiveTo determine the reproducibility of AdnaTest CTC AR-V7 testing, and associations with clinical characteristics, CellSearch CTC counts, tumour biopsy AR-V7 protein expression and overall survival (OS). DESIGN, SETTING, AND

participantsCTC AR-V7 status was determined for 227 peripheral blood samples, from 181 mCRPC patients with CTC counts (202 samples; 136 patients) and matched mCRPC biopsies (65 samples; 58 patients). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: CTC AR-V7 status was associated with clinical characteristics, CTC counts, and tissue biopsy AR-V7 protein expression. The association of CTC AR-V7 status and other baseline variables with OS was determined. RESULTS AND LIMITATIONS: Of the samples, 35% were CTC+/AR-V7+. CTC+/AR-V7+ samples had higher CellSearch CTC counts (median CTC; interquartile range [IQR]: 60, 19-184 vs 9, 2-64; Mann-Whitney test p<0.001) and biopsy AR-V7 protein expression (median H-score, IQR: 100, 63-148 vs 15, 0-113; Mann-Whitney test p=0.004) than CTC+/AR-V7- samples. However, both CTC- (63%) and CTC+/AR-V7- (62%) patients had detectable AR-V7 protein in contemporaneous biopsies. After accounting for baseline characteristics, there was shorter OS in CTC+/AR-V7+ patients than in CTC- patients (hazard ratio [HR] 2.13; 95% confidence interval [CI] 1.23-3.71; p=0.02); surprisingly, there was no evidence that CTC+/AR-V7+ patients had worse OS than CTC+/AR-V7- patients (HR 1.26; 95% CI 0.73-2.17; p=0.4). A limitation of this study was the heterogeneity of treatment received.

conclusionsStudies reporting the prognostic relevance of CTC AR-V7 status must account for CTC counts. Discordant CTC AR-V7 results and AR-V7 protein expression in matched, same-patient biopsies are reported. PATIENT SUMMARY: Liquid biopsies that determine circulating tumour cell androgen receptor splice variant-7 status have the potential to impact treatment decisions in metastatic castration-resistant prostate cancer patients. Robust clinical qualification of these assays is required before their routine use.

Indexed as

Neoplastic Cells, CirculatingProstatic Neoplasms, Castration-ResistantAlternative SplicingBiopsyCell CountDrug Resistance, NeoplasmGenetic TechniquesHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPrognosisProtein IsoformsReceptors, AndrogenReproducibility of ResultsAR protein, humanProtein IsoformsReceptors, AndrogenAndrogen receptorAndrogen receptor splice variant-7BiomarkerLiquid biopsyMetastatic castration-resistant prostate cancerPrognostic

Identifiers

PMID31036442
OpenAlexW2941797036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.